Recombinant Ephb4-Hsa Fusion Protein
BRAF Gene Mutation
University of Southern Californiaprotein_peptidePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the BRAF Gene Mutation cohort.
View all 22 →
Same molecule, other indications
Recombinant Ephb4-Hsa Fusion Protein is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →